Combination of Targeted Radiotherapy with Other Therapeutic Modalities for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 255
Special Issue Editors
Interests: nanomedicine; radiochemistry; theranostics; molecular imaging; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a complex disease that requires a multifaceted approach to treatment. Targeted radiotherapy has emerged as a promising therapeutic modality for cancer treatment, as it selectively delivers radiation to cancer cells while minimizing damage to healthy tissues; however, the use of targeted radiotherapy alone may not always provide sufficient efficacy in controlling the disease. Thus, the combination of targeted radiotherapy with other therapeutic modalities has gained increasing attention in recent years.
This Special Issue in Pharmaceutics focuses on the combination of targeted radiotherapy with other therapeutic modalities for cancer treatment, including, but not limited to, chemotherapy, immunotherapy, phototherapies, and thermal therapies. This Special Issue aims to highlight the potential of these combination therapies in improving treatment efficacy, reducing toxicity, and overcoming treatment resistance. One promising approach to combining targeted radiotherapy with other therapeutic modalities involves the use of multifunctional nanoparticles. These nanoparticles can be designed to carry both therapeutic and diagnostic payloads, allowing for the targeted delivery of multiple therapies to cancer cells while minimizing damage to healthy tissues.
The goal of this Special Issue is to provide a comprehensive overview of the latest possibilities for the combination of radiotherapy with other therapeutic modalities for cancer treatment, particularly in the context of multifunctional nanoparticles. This Special Issue seeks original research articles, review articles, and clinical studies that investigate the combinatorial therapy approach.
Dr. Nisarg Soni
Dr. Swarbhanu Sarkar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted radionuclide therapy
- multimodal nanoparticles
- cancer
- personalized medicine
- theranostics
- nanomedicine
